The Proteasome Inhibitor, MG132, Attenuates Diabetic Nephropathy by Inhibiting SnoN Degradation In Vivo and In Vitro

Figure 1

Therapeutic effects of the proteasome inhibitor, MG132, on diabetes-induced general changes and renal function. Diabetic rats were divided into two groups: a diabetic control group (DC group) and a diabetes therapy group (DT group) treated daily with MG132 (0.05 mg/kg). Meanwhile, the NC and DC groups received daily injections of equivalent volumes of citrate buffer. After 6 or 8 weeks, fasting blood glucose (a), body weight (b), 2-hour urine protein (c), ACR (d), and BUN (e) levels were examined before and after treatment with MG132. Data are presented as means ± SD. ^∗𝑃<0.05 versus NC group; ^#𝑃<0.05 versus DC group.

(a)

(b)

(c)

(d)

(e)